Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $2.73 in the prior trading day, Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $2.88, up 5.49%. In other words, the price has increased by $5.49 from its previous closing price. On the day, 1.27 million shares were traded. ACRS stock price reached its highest trading level at $2.895 during the session, while it also had its lowest trading level at $2.71.
Ratios:
Our goal is to gain a better understanding of ACRS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.92 and its Current Ratio is at 3.92. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 28, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 312034304 and an Enterprise Value of 218366288. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.82 while its Price-to-Book (P/B) ratio in mrq is 2.60. Its current Enterprise Value per Revenue stands at 13.872 whereas that against EBITDA is -3.322.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.63, which has changed by -0.2923833 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $4.24, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 32.03%, while the 200-Day Moving Average is calculated to be 65.31%.
Shares Statistics:
The stock has traded on average 1.20M shares per day over the past 3-months and 1180330 shares per day over the last 10 days, according to various share statistics. A total of 108.34M shares are outstanding, with a floating share count of 92.51M. Insiders hold about 14.62% of the company’s shares, while institutions hold 67.19% stake in the company. Shares short for ACRS as of 1763078400 were 3899510 with a Short Ratio of 3.25, compared to 1760486400 on 4689649. Therefore, it implies a Short% of Shares Outstanding of 3899510 and a Short% of Float of 4.29.
Earnings Estimates
A detailed examination of Aclaris Therapeutics Inc (ACRS) is currently in progress, with 4.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.15 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.29 and -$0.54 for the fiscal current year, implying an average EPS of -$0.47. EPS for the following year is -$0.57, with 5.0 analysts recommending between -$0.3 and -$0.87.
Revenue Estimates
6 analysts predict $2.14M in revenue for. The current quarter. It ranges from a high estimate of $3.3M to a low estimate of $1M. As of. The current estimate, Aclaris Therapeutics Inc’s year-ago sales were $9.21MFor the next quarter, 6 analysts are estimating revenue of $2.3M. There is a high estimate of $3.3M for the next quarter, whereas the lowest estimate is $1M.
A total of 6 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $9.83M, while the lowest revenue estimate was $7.5M, resulting in an average revenue estimate of $8.56M. In the same quarter a year ago, actual revenue was $18.72MBased on 7 analysts’ estimates, the company’s revenue will be $6.83M in the next fiscal year. The high estimate is $13.2M and the low estimate is $900k.
